{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T22:20:34Z","timestamp":1792275634390,"version":"4.4.0"},"reference-count":18,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Dermatol Surg","DS"],"published-print":{"date-parts":[[2021,1]]},"abstract":"<jats:sec>\n            <jats:title>BACKGROUND<\/jats:title>\n            <jats:p>A wide lower face and a square jaw are considered esthetic problems, particularly in Asia.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>OBJECTIVE<\/jats:title>\n            <jats:p>To investigate the optimal dose of a novel botulinum toxin (prabotulinum toxin A) for treating masseteric hypertrophy.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>METHODS<\/jats:title>\n            <jats:p>Ninety subjects with masseteric hypertrophy were randomly divided into 5 groups and treated with placebo (A, normal saline) or prabotulinum toxin A (B: 24, C: 48, D: 72, and E: 96 units). Photography, ultrasonography, and 3-dimensional imaging were performed before and after injection at baseline and at 4, 8, 12, and 16 weeks after treatment. The participants also rated their satisfaction.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>RESULTS<\/jats:title>\n            <jats:p>Masseter thickness significantly reduced in all groups at 12 weeks, compared with that in the placebo group. A dose-dependent reduction in masseter thickness was observed at the resting and maximal clenching positions. Sonography and 3-dimensional imaging revealed a gradual reduction in masseter thickness and volume, respectively, during the first 12 weeks. Despite being slightly effective, a dose of 24 units might be insufficient for resolving square face problems. Patients in Group E reported discomfort during jaw movement.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>CONCLUSION<\/jats:title>\n            <jats:p>Prabotulinum toxin A could effectively improve lower face contour without major complications, with an optimal dose of 48 to 72 units, followed by reinjection after 12 weeks.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/dss.0000000000002475","type":"journal-article","created":{"date-parts":[[2020,12,19]],"date-time":"2020-12-19T01:53:36Z","timestamp":1608342816000},"page":"e5-e9","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":21,"title":["Efficacy and Safety of a Novel Botulinum Toxin A for Masseter Reduction: A Randomized, Double-Blind, Placebo-Controlled, Optimal Dose-Finding Study"],"prefix":"10.1097","volume":"47","author":[{"given":"Ji Yeon","family":"Hong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guk Jin","family":"Jeong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tae-Rin","family":"Kwon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jong Hwan","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kapsok","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beom Joon","family":"Kim","sequence":"additional","affiliation":[{"name":"All authors are affiliated with the Department of Dermatology, College of Medicine, Chung-Ang University, Seoul, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20250731","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1080\/09546634.2016.1263382","article-title":"The efficacy of two formulations of botulinum toxin type A for masseter reduction: a split-face comparison study","volume":"28","author":"Wanitphakdeedecha","year":"2017","journal-title":"J Dermatolog Treat"},{"key":"R2-20250731","first-page":"477","article-title":"Botulinum toxin type A treatment for contouring of the lower face","volume":"29","author":"Park","year":"2003","journal-title":"Dermatol Surg"},{"key":"R3-20250731","first-page":"484","article-title":"Effects of botulinum toxin type A on bilateral masseteric hypertrophy evaluated with computed tomographic measurement","volume":"29","author":"Kim","year":"2003","journal-title":"Dermatol Surg"},{"key":"R4-20250731","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1097\/PRS.0b013e3181d0ad03","article-title":"Botulinum toxin type A for the treatment of hypertrophy of the masseter muscle","volume":"125","author":"Kim","year":"2010","journal-title":"Plast Reconstr Surg"},{"key":"R5-20250731","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1159\/000349984","article-title":"RimabotulinumtoxinB versus OnabotulinumtoxinA in the treatment of masseter hypertrophy: a 24-week double-blind randomized split-face study","volume":"226","author":"Lee","year":"2013","journal-title":"Dermatology"},{"key":"R6-20250731","doi-asserted-by":"crossref","first-page":"209e","DOI":"10.1097\/PRS.0000000000000371","article-title":"Classification of masseter hypertrophy for tailored botulinum toxin type A treatment","volume":"134","author":"Xie","year":"2014","journal-title":"Plast Reconstr Surg"},{"key":"R7-20250731","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1097\/00042728-200505000-00002","article-title":"Effects of botulinum toxin type A on contouring of the lower face","volume":"31","author":"Choe","year":"2005","journal-title":"Dermatol Surg"},{"key":"R8-20250731","first-page":"225","article-title":"Ultrasonographic study on the masseter muscle thickness of adult Korean. Korea","volume":"31","author":"Lee","year":"2001","journal-title":"J Orthod"},{"key":"R9-20250731","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1097\/DSS.0000000000001920","article-title":"Efficacy and safety of prabotulinumtoxin A and onabotulinumtoxin A for crow's feet: a phase 3, multicenter, randomized, double-blind, split-face study","volume":"45","author":"Cheon","year":"2019","journal-title":"Dermatol Surg"},{"key":"R10-20250731","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1001\/archfaci.6.3.188","article-title":"Botulinum toxin for masseter reduction in Asian patients","volume":"6","author":"Ahn","year":"2004","journal-title":"Arch Facial Plast Surg"},{"key":"R11-20250731","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.3892\/etm.2014.1552","article-title":"A comparative study of the efficacy and safety of radiofrequency ablation and botulinum toxin A in treating masseteric hypertrophy","volume":"7","author":"Huang","year":"2014","journal-title":"Exp Ther Med"},{"key":"R12-20250731","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.ajodo.2006.10.043","article-title":"Bimaxillary protrusion with masseter muscle hypertrophy treated with titanium screw anchorage and masseter surgical reduction","volume":"135","author":"Hashimoto","year":"2009","journal-title":"Am J Orthod Dentofacial Orthop"},{"key":"R13-20250731","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1016\/S0278-2391(99)90493-7","article-title":"Aesthetic uses of botulinum toxin A","volume":"57","author":"Niamtu","year":"1999","journal-title":"J Oral Maxillofac Surg"},{"key":"R14-20250731","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/s00266-007-0081-8","article-title":"Botulinum toxin a for lower facial contouring: a prospective study","volume":"31","author":"Yu","year":"2007","journal-title":"Aesthet Plast Surg"},{"key":"R15-20250731","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1097\/00006534-199811000-00013","article-title":"Variability of the midfacial muscles: analysis of 50 hemifacial cadaver dissections","volume":"102","author":"Pessa","year":"1998","journal-title":"Plast Reconstr Surg"},{"key":"R16-20250731","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1097\/DSS.0000000000000223","article-title":"The risorius muscle: anatomic considerations with reference to botulinum neurotoxin injection for masseteric hypertrophy","volume":"40","author":"Bae","year":"2014","journal-title":"Dermatol Surg"},{"key":"R17-20250731","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1054\/bjps.2000.3526","article-title":"A prospective study of the effect of botulinum toxin A on masseteric muscle hypertrophy with ultrasonographic and electromyographic measurement","volume":"54","author":"To","year":"2001","journal-title":"Br J Plast Surg"},{"key":"R18-20250731","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1093\/asj\/sjx102","article-title":"Does botulinum toxin injection into masseter muscles affect subcutaneous thickness?","volume":"38","author":"Park","year":"2018","journal-title":"Aesthet Surg J"}],"container-title":["Dermatologic Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/DSS.0000000000002475","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T22:12:18Z","timestamp":1753999938000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/DSS.0000000000002475"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":18,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/dss.0000000000002475","relation":{},"ISSN":["1076-0512","1524-4725"],"issn-type":[{"value":"1076-0512","type":"print"},{"value":"1524-4725","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1]]}}}